GSK plc Completes Acquisition of 35Pharma Inc.
Ticker: GSK · Form: 6-K · Filed: Apr 15, 2026
Sentiment: neutral
Topics: acquisition, merger, corporate-action
TL;DR
GSK just bought 35Pharma Inc. - deal closed 4/15/26.
AI Summary
GSK plc announced on April 15, 2026, the completion of its acquisition of 35Pharma Inc. The filing is a Form 6-K, reporting this significant corporate event for the foreign issuer.
Why It Matters
This acquisition signifies GSK's strategic expansion and integration of new assets or capabilities, potentially impacting its market position and future product pipeline.
Risk Assessment
Risk Level: low — This is a routine 6-K filing announcing the completion of an acquisition, which is a standard corporate event.
Key Players & Entities
- GSK plc (company) — Acquiring company
- 35Pharma Inc. (company) — Acquired company
- April 15, 2026 (date) — Date of acquisition completion
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose of this 6-K filing is to report the completion of GSK plc's acquisition of 35Pharma Inc.
When was the acquisition of 35Pharma Inc. completed?
The acquisition of 35Pharma Inc. was completed on April 15, 2026.
What is the CIK number for GSK plc?
The CIK number for GSK plc is 0001131399.
What type of form is this SEC filing?
This SEC filing is a Form 6-K, which is a report of a foreign issuer.
Where is GSK plc's mailing and business address listed?
GSK plc's mailing and business address is listed as 79 NEW OXFORD STREET LONDON United Kingdom WC1A 1DG.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 15, 2026 regarding GSK plc (GSK).